Canadian Cohort of Aquablation, a Robotically Executed, Surgeon-guided, High-pressure Water Jet Ablation Therapy for Endoscopic Resection of Prostate Tissue in Benign Prostatic Hyperplasia (BPH)

What this Trial Is About

Researchers are evaluating Aquablation therapy, a robotically executed, surgeon-guided high-pressure water jet procedure, for men with benign prostatic hyperplasia (BPH) in a Canadian patient group. The goal is to document the clinical outcomes of this treatment for BPH, a condition involving prostate enlargement that affects urinary function. Patients will be followed as part of standard care for up to three years to gather data on the therapy's effects. The study focuses on Aquablation as the primary intervention, which involves endoscopic resection of prostate tissue using high-pressure water jets guided by robotic technology and a surgeon. There are no comparison groups mentioned, as this is an observational study documenting outcomes after Aquablation therapy. The treatment is delivered once, and patients are monitored over time to assess changes. Participants will be evaluated at multiple points including baseline, 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months after surgery. Assessments include maximum urine flow rate (Q-max), post-void residual (PVR) urine volume, prostate volume, patient questionnaires, and monitoring for adverse events. Follow-up visits align with routine care to track the therapy's impact and safety over three years.

Aquablation in Benign Prostatic Hyperplasia in Canada